Hanhai Xinmei

Wuhan Hanhai Xinmei Biotechnology Co., Ltd. (hereinafter referred to as "Hanhai Xinmei") was established in 2015. It is a high-tech enterprise specializing in the research and development, production, application, and technical services of specialty enzymes.
The company possesses technology platforms including enzyme gene mining and performance characterization, enzyme molecular optimization and modification, organic custom synthesis, and synthetic biology. Based on these technology platforms, it has developed nearly 100 types of in vitro diagnostic reagent raw materials. Products include diagnostic enzymes, coenzymes, enzyme substrates, enzyme mixtures, etc. The application fields cover the manufacturing of in vitro diagnostic reagents such as biochemical diagnostics, immunodiagnostics, molecular diagnostics, blood coagulation and blood gas, and biosensors. The company also offers customized services for in vitro diagnostic reagents, providing customers with in vitro diagnostic reagent development solutions based on core raw material technologies. Currently, the company has completed customized formula research for nearly 70 biochemical products. The company has a pharmaceutical-grade specialty enzyme production system with large domestic production scale and high equipment standards, and has supplied products to over 80 domestic in vitro diagnostic reagent manufacturers and 42 foreign businesses in 25 countries.
In early 2020, in response to market demand, the company quickly established a molecular diagnostics raw material research and development platform, shouldering the responsibility of a Chinese raw material enterprise in addressing the global "novel coronavirus" pandemic outbreak. In an extremely short period, the company completed the development of core raw materials for COVID-19 testing, including proteinase K for molecular diagnostics, dNTP, Taq DNA polymerase, RT-PCR master MIX, etc., and was included in the "Key Enterprises for Epidemic Prevention and Control" list by the Wuhan Development and Reform Commission.
Since its establishment, Hanhai Xinmei has adhered to the principle of "technological innovation driving the progress of the biological industry, continuously creating value for customers," boldly investing in highly challenging projects on the research and development front, and has continuously achieved "zero breakthroughs" in the domestic specialty enzyme preparation industry. The company's development has also been recognized by the industry, receiving multiple honors such as the first CACLP "Junyang Cup" Value Investment Award, "Wuhan Little Giant Enterprise," and "Optics Valley Gazelle Enterprise," and has obtained national high-tech enterprise certification.
On the future development path, the company will, while consolidating existing products and services, continuously expand product fields and enrich product varieties, uphold the core values of "innovation foremost, pursuit of excellence, courage to take responsibility, and win-win cooperation," and strive tirelessly to build Hanhai Xinmei into a "first-class supplier of specialty enzyme products and services"!